First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $919.7B — +11.3% growth in a single year.
What Moves the Stock
1Leqembi commercial uptake metrics: quarterly prescription volumes, new patient starts, infusion center capacity expansion, and payer coverage decisions beyond current CMS restrictions
2Regulatory milestones: subcutaneous formulation approval timeline (expected to improve convenience vs IV infusion), label expansion opportunities, international approvals in EU and China
3Lenvima lifecycle management: new indication approvals, combination therapy data with checkpoint inhibitors, competitive positioning against emerging TKIs in oncology
4Pipeline readouts: Phase 3 data for MORAb-202 (folate receptor alpha ADC), E7090 (FGF inhibitor), and other mid-stage oncology assets
5Yen/dollar exchange rate fluctuations given ~35% US revenue exposure and yen-denominated cost base
6Oncology franchise (~45-50% of revenue): Lenvima (multi-kinase inhibitor for thyroid, renal, hepatocellular carcinoma), Halaven (breast cancer)
7Neurology franchise (~30-35%): Leqembi (Alzheimer's), Fycompa (epilepsy), legacy Aricept generics in Japan
8Other therapeutic areas (~15-20%): Gastrointestinal, cardiovascular, dermatology products primarily in Asian markets
Rising interest rates have moderate negative impact through two channels: (1) Higher discount rates compress NPV of long-duration pipeline…
Watch on earnings: Leqembi quarterly prescription data (IQVIA, Symphony Health): new patient starts, discontinuation rates, geographic penetration, CMS coverage policy updates: expansion beyond CED (Coverage with Evidence Development) framework would dramatically expand addressable market, Yen/dollar exchange rate (DEXJPUS): impacts revenue translation and cost competitiveness.
One Sentence Summary:
Eisai: the story is balanced — leqembi commercial uptake metrics: quarterly prescription volumes, new patient starts, infusion center capacity expansion.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.